Key statistics
As of last trade, Cyclacel Pharmaceuticals Inc (CYCCP:NAQ) traded at 7.49, 42.67% above the 52 week low of 5.25 set on Nov 08, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 7.49 |
---|---|
High | 7.49 |
Low | 7.49 |
Bid | 7.00 |
Offer | 8.25 |
Previous close | 7.49 |
Average volume | 1.10k |
---|---|
Shares outstanding | 1.97m |
Free float | 1.88m |
P/E (TTM) | -- |
Market cap | 1.76m USD |
EPS (TTM) | -16.14 USD |
Annual div (ADY) | -- |
---|---|
Annual div yield (ADY) | -- |
Div ex-date | Jan 19 2024 |
Div pay-date | Feb 01 2024 |
Data delayed at least 15 minutes, as of Oct 07 2024 16:53 BST.
More ▼
Announcements
- Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
- Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study
- Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference
- Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter
- Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update
- Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results
- Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions
- Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting
- Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for Cancer
- Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
More ▼